Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer
A Randomised Placebo-controlled Study Evaluating the Role of Pyridoxine in Controlling Capecitabine-induced Hand-foot Syndrome
Sponsor: Cambridge University Hospitals NHS Foundation Trust
A PHASE3 clinical study on Breast Cancer and Colorectal Cancer, this trial is ongoing. The trial is conducted by Cambridge University Hospitals NHS Foundation Trust and has accumulated 6 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE3
First recorded
Dec 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cambridge University Hospitals NHS Foundation Trust
For direct contact, visit the study record on ClinicalTrials.gov .